Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cataract & MIGS cases in District of Columbia: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 7% on average (255 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 29 | 2,749 | 24% |
| 2020 | 22 | 1,867 | 26% |
| 2021 | 25 | 2,840 | 30% |
| 2022 | 26 | 2,892 | 33% |
| 2023 | 31 | 3,454 | 37% |
| 2024 | 29 | 3,191 | 39% |
| 2025 from claims | – | 3,199 2,936–3,385 | 41% |
| 2026 forecast | – | 3,375 2,970–3,895 | 40% |
| 2027 forecast | – | 3,526 3,014–4,202 | 41% |
| 2028 forecast | – | 3,683 3,073–4,510 | 42% |
| 2029 forecast | – | 3,847 3,142–4,824 | 42% |
| 2030 forecast | – | 4,017 3,219–5,148 | 43% |
Cataract extraction with IOL, with and without glaucoma stents; the ASC volume engine. Professional codes (what the surgeon bills): CPT 66984, 66982, 66989, 66991, 66987, 66988, 65820, 66174, 66183, 0671T, 0449T.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 74% of the cases CMS names in District of Columbia; 13 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 5% hospital outpatient, 92% surgery center, 3% office. The share outside the hospital has moved +6 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 638 | 117,786−2.6%/yr | −2.6%/yr | 53.6 | 88% | 129,100 in 2030+1.5%/yr |
| Florida | 588 | 114,602−2.3%/yr | −2.3%/yr | 50.4 | 95% | 126,900 in 2030+1.7%/yr |
| North Carolina | 248 | 74,301+0.5%/yr | +0.5%/yr | 73.4 | 66% | 87,500 in 2030+2.8%/yr |
| Virginia | 225 | 73,424+1%/yr | +1%/yr | 69.1 | 87% | 82,800 in 2030+2%/yr |
| Tennessee | 167 | 60,859+2.6%/yr | +2.6%/yr | 85.1 | 93% | 72,000 in 2030+2.8%/yr |
| Georgia | 221 | 47,191−3.3%/yr | −3.3%/yr | 53.6 | 89% | 50,000 in 2030+1%/yr |
| South Carolina | 144 | 45,000+1.8%/yr | +1.8%/yr | 64.6 | 89% | 59,900 in 2030+4.9%/yr |
| Maryland | 198 | 39,250−1.2%/yr | −1.2%/yr | 44.0 | 91% | 41,300 in 2030+0.8%/yr |
| Alabama | 102 | 35,688−2.7%/yr | −2.7%/yr | 79.5 | 83% | 29,500 in 2030−3.1%/yr |
| Oklahoma | 85 | 29,510−2.8%/yr | −2.8%/yr | 60.0 | 81% | 28,700 in 2030−0.5%/yr |
| Kentucky | 91 | 27,713−3.2%/yr | −3.2%/yr | 59.3 | 80% | 29,700 in 2030+1.2%/yr |
| Louisiana | 120 | 22,385−5.1%/yr | −5.1%/yr | 53.7 | 61% | 20,400 in 2030−1.5%/yr |
| Mississippi | 74 | 21,062−3.1%/yr | −3.1%/yr | 55.3 | 96% | 21,400 in 2030+0.3%/yr |
| Arkansas | 64 | 19,041−6%/yr | −6%/yr | 49.6 | 87% | 22,100 in 2030+2.5%/yr |
| Delaware | 21 | 8,893+2%/yr | +2%/yr | 51.3 | 94% | 10,900 in 2030+3.5%/yr |
| West Virginia | 40 | 8,511−8.6%/yr | −8.6%/yr | 40.0 | 46% | 6,820 in 2030−3.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Vitreoretinal surgery | 3 | 175−2.1%/yr | −2.1%/yr | 2.81.1× | 51% | 260 in 2030+6.9%/yr |
Cataract & MIGS in every state, and its device makers · Every procedure market in District of Columbia · Every state · Compare with Texas
Alcon leads with 54% of company spending on these surgeons in 2025, +42 pts on 2024.
In 2025, 12 companies reported engagement with District of Columbia’s surgeons worth $17K in consulting, speaking, meals and travel tied to these products, about $598 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.